Physician profile
Allie Jackson
NPI 1053983734
$1,890.81
in general payments reported to CMS, 2019-2025
17 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $309 · 2023: $472 · 2024: $763 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.64 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $352.13 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Novo Nordisk INC | $192.95 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $178.71 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $86.99 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $85.04 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $78.49 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $71.94 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.69 | 2021-2024 | Jardiance |
| Grifols USA, LLC | $53.73 | 2022-2024 | Prolastin-C Liquid |
| Indivior INC. | $44.27 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.45 | 2024 | Caplyta |
| Lundbeck LLC | $29.13 | 2024 | Rexulti |
| Medtronic, INC. | $20.56 | 2024 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $20.18 | 2024 | Austedo Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.17 | 2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $13.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allie Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.